The current COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, is the current focus of numerous drug therapies and vaccine candidates. We have seen swift action from regulatory authorities to fast-track clinical programmes to find a cure or treatment. However, Bruno Speder and Robin Rogiers at SGS question whether it would it be possible that human challenge testing – or controlled infection models – could offer insights into developing therapies.